The Connective Tissue Code: Understanding Ehlers-Danlos Syndrome.

Most people first hear about Ehlers-Danlos Syndrome (EDS) as a collagen disorder. That is a useful starting point, but it is not the whole map.

Collagen is one of the body's major structural materials. It helps give strength and shape to skin, blood vessels, ligaments, tendons, fascia, organs, and the sclera of your eyes. In some forms of EDS, the problem is directly tied to collagen itself: how it is built, processed, or assembled.

But connective tissue is not just collagen. It is a living, regulated system. The body has to build the matrix, cross-link it, remodel it, signal through it, repair it, and keep it in balance. When the genes or pathways regulating that system are disrupted, the downstream result can still look like "bad connective tissue" even when the original problem is not simply a collagen recipe error.

That distinction matters. For many people, especially those with hypermobile EDS (hEDS), the visible symptoms are downstream effects: loose joints, unstable tissue, fragile recovery, pain, fatigue, dysautonomia, and immune overreaction. The label names the pattern. It does not always name the root cause.

The 13 Subtypes

Ehlers-Danlos Syndrome is an umbrella classification for 13 heritable connective tissue disorders. Some subtypes have known single-gene causes involving collagen or collagen-processing pathways. Others involve different parts of the connective tissue system. The clinical picture changes depending on which tissue, pathway, and gene are involved.

Key subtypes include:

• Classical EDS (cEDS): Characterized clinically by marked skin hyperextensibility, widened atrophic scarring, and generalized joint hypermobility.
• Vascular EDS (vEDS): The most severe and life-threatening phenotype, caused by a defect in type III collagen—the protein supporting the walls of blood vessels and hollow organs (e.g., the intestines and uterus), placing patients at high risk for spontaneous aneurysms and arterial ruptures.
• Hypermobile EDS (hEDS): The most commonly diagnosed EDS subtype. This subtype features widespread joint instability, chronic musculoskeletal pain, and frequent overlap with autonomic dysfunction (including POTS-like physiology) and mast-cell-related symptoms.

Note: hEDS is still diagnosed clinically using the 2017 international diagnostic criteria. No molecular test currently establishes hEDS by itself. Emerging research, including work on KLK-related pathways, suggests that hEDS may involve more than one genetic route into connective tissue dysfunction. That science is moving quickly, but it has not yet replaced clinical diagnosis.

Structure, Regulation, and Downstream Symptoms

A useful way to think about EDS is this: connective tissue symptoms can come from problems in the material itself, problems in how the body regulates that material, or both.

Some pathways influence how connective tissue is remodeled. Some affect inflammation. Some touch blood vessel tone, pain signaling, wound healing, or mast cell behavior. Researchers are actively studying systems like extracellular matrix regulation, protease activity, lysyl oxidase pathways, and the bradykinin-kinin system because those systems can influence how tissue feels and functions downstream.

This is why EDS can look bigger than "loose joints." If the underlying issue affects tissue regulation, blood vessel behavior, immune signaling, or nervous system compensation, the person may experience a whole-body pattern rather than one isolated orthopedic problem.

The Clinical Reality of Joint Instability

In a healthy individual, firm ligaments establish the physiological boundaries of a joint's range of motion. For an EDS patient, this ligamentous laxity means the joint lacks a hard stop.

The result is chronic luxations (full dislocations) and subluxations (partial dislocations). Patients routinely experience structural joint failure during mundane physiological motions—such as sleeping, reaching, or turning a steering wheel.

Over time, this repeated mechanical stress on unstable joints can accelerate cartilage wear and increase the risk of early-onset osteoarthritis — a risk worth managing proactively, not an inevitable outcome. The surrounding muscles also have to compensate constantly for what the ligaments aren't doing, leading to chronic spasm and fatigue that can be as disabling as the joint instability itself.

Systemic Connective Tissue Involvement

Connective tissue and connective-tissue regulation affect organ systems far outside the usual purview of rheumatology. Common associated manifestations can include:

• Gastrointestinal: Gastroparesis (delayed gastric emptying), hiatal hernias, and severe intestinal motility issues resulting from a lack of structural tone in the gut lining.
• Neurological: Headaches, proprioception problems, nerve irritation, and, in some patients, craniocervical or spinal instability that requires specialist evaluation.
• Dental & Maxillofacial: Resistance to local anesthetics like lidocaine is frequently reported by EDS patients and is increasingly recognized by practitioners — if standard dental numbing doesn't work well for you, mention EDS and ask about alternative protocols. Dental enamel can also be more fragile, and TMJ dysfunction is common.
• Dermatological & Vascular: Capillary fragility resulting in profound, unexplained ecchymosis (bruising), delayed wound healing, and transparent skin.

Why POTS and MCAS Often Enter the Conversation

POTS and MCAS are often discussed beside EDS because many patients live with overlapping patterns. That does not mean every person with EDS has POTS or MCAS, and it does not mean POTS is a root-cause diagnosis.

POTS describes a measurable orthostatic pattern: the body struggles to regulate circulation when upright, and heart rate rises to compensate. Something is driving that physiology. In some people, connective tissue laxity, low blood volume, vascular tone, immune changes, post-viral illness, medications, deconditioning after illness, or other factors may all be part of the picture.

MCAS describes inappropriate mast cell activation: the immune system releasing mediators too easily, too often, or in response to triggers that should not cause that level of reaction. When mast cell activation, dysautonomia, and connective tissue symptoms travel together, patients often call it "the Trifecta." That phrase is not a formal single diagnosis. It is a useful shorthand for a pattern many patients recognize.

Diagnostic Evaluation: The Beighton Score

The standard clinical assessment for generalized joint hypermobility heavily relies on the Beighton Score—a 9-point screening tool measuring extreme flexibility (e.g., placing palms flat on the floor with knees locked, extending the fifth digit past 90 degrees).

However, leading researchers and patient advocates widely criticize the Beighton clinical test for being inherently narrow—it predominantly measures mobility in younger female phenotypes and completely excludes central load-bearing joints like the shoulders, hips, and jaw. Consequently, passing the Beighton Score constitutes only the first of three rigorous criteria required for a formal hEDS diagnosis.

Validating the Patient Experience

Navigating an EDS diagnosis often means enduring years of medical dismissal — which is its own kind of exhaustion. Patients frequently appear "young, healthy, and flexible," which makes the invisible suffering easy to overlook. But the chronic pain is real, the mechanical instability is measurable, and the fatigue is a direct physiological consequence of a body that works twice as hard just to hold itself together.

Finding a geneticist or rheumatologist who is genuinely hypermobility-literate is the most important first step. It exists. Keep looking.

If this is your first stop in the Captain's Log, keep going. Start with POTS if standing, heat, showers, or exertion make your body crash. Start with MCAS if foods, smells, medications, temperature shifts, or "random" reactions seem to set off multiple body systems. Start with genetics if your family history looks suspicious or you want to understand why hEDS remains clinically diagnosed while the research catches up.

Stay Salty!